HomeCoronary diseaseDrug-eluting stents

Drug-eluting stents

1-Year Clinical Outcomes of Everolimus-Eluting Bioresorbable Vascular Scaffolds in Diabetic Patients

Original title: 1-Year Clinical Outcomes of Diabetic Patients Treated With Everolimus-Eluting Bioresorbable Vascular Scaffolds A Pooled Analysis of...

Higher percentage of strut coverage in biodegradable polymer DES vs. durable polymer DES. Strut level OCT analyses

Original title: Randomized comparison of strut coverage between Nobori biolimus-eluting and sirolimus-eluting stents: an optical coherence tomography analysis. Reference:...

Angioplasty in sirolimus – eluting stent restenosis is safe and effective beyond the change of drug.

Original title: Sirolimius-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stents restenosis: Results from the...

Best results of angioplasty with DES guided by IVUS versus angiography only

Original title: Intravascular Ultrasound-Guided Implantation of Drug-Eluting Stents to Improve Outcome. A Meta-Analysis. Reference: Jae-Sik Jang et al. J Am...

At least one month of antiplatelet seems sufficient after a zotarolimus -eluting stent

Original title: Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months...

3rd generation zotarolimus-eluting stent non- inferior to everolimus

Original title: Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a...

Malapposition in drug-eluting stents. Much more common and much less serious than we thought

Original title: Incidences, Predictors, and Clinical Outcomes of Acute and Late Stent Malapposition Detected by Optical Coherence Tomography...

Primary angioplasty with 2nd generation drug-eluting stents

Original title: Stent thrombosis with second-generation drug-eluting stents compared with bare-metal stents: Network meta-analysis of primary percutaneous coronary...